ADAGIO MEDICAL Investor Presentation | June 2024 1 DISCLAIMER This investor presentation is for informational purposes only to assist interested parties in making their.
In a small, single-center trial, the novel Marshall-Plan ablation strategy improved 10-month arrhythmia recurrence compared with pulmonary vein isolation alone for persistent atrial fibrillation, a speaker reported.“After 10 months of follow up, the success rate in the Marshall-Plan group was significantly better (87%) compared to the PVI only group (70%),” Nicolas Derval, MD, head of